2-Amino-N-[4-[2-[[(2R)-2-Hydroxy-2-Phenylethyl]Amino]Ethyl]Phenyl]-4-Thiazoleacetamide

The molecule designated by the IUPAC nomenclature 2-Amino-N-[4-[2-[[(2R)-2-Hydroxy-2-Phenylethyl]Amino]Ethyl]Phenyl]-4-Thiazoleacetamide is recognized globally as mirabegron. Its molecular formula is C₂₁H₂₄N₄O₂S, corresponding to a monoisotopic mass of 396.162 Da, and its CAS registry number is 223673-61-8. The substance is an active pharmaceutical ingredient (API) classified as a β₃-adrenoceptor agonist, structurally defined by a thiazole ring bearing a free 2-amino group and an acetamide side chain that terminates in a secondary amine-linked phenylethyl moiety possessing an (R)-configured benzylic alcohol. Pharmacopoeial monographs—including those adopted by the United States Pharmacopeia (USP) and the European Pharmacopoeia (Ph. Eur.)—specify a white to off-white crystalline powder with a melting endotherm onset near 138 °C to 142 °C as determined by differential scanning calorimetry at a scanning rate of 10 K/min. The API is practically insoluble in water (<0.1 mg/mL at 25 °C) and exhibits pH-dependent solubility that declines sharply above pH 5.0, a critical parameter governing both oral absorption and dissolution method development.

What Differentiates Mirabegron from Muscarinic Receptor Antagonists?

Conventional pharmacotherapy for overactive bladder has relied on competitive antagonism of muscarinic M₂ and M₃ receptors, an approach that depresses detrusor smooth muscle contractility at the cost of gastrointestinal hypomotility, dry mouth, and cognitive burden. Mirabegron operates through an orthogonal pathway: it activates the β₃-adrenoceptor (gene ADRB3) expressed on the detrusor, stimulating adenylyl cyclase and raising intracellular cyclic adenosine monophosphate (cAMP) concentrations without direct muscarinic blockade. Binding affinity data generated using recombinant human receptors show a pK_i of 8.0 to 8.3 for the β₃ subtype, whereas affinity at β₁- and β₂-adrenoceptors is approximately 150-fold and 30-fold lower, respectively. This selectivity window is functionally confirmed in isolated human bladder strips, where mirabegron induces concentration-dependent relaxation with an EC₅₀ of 5.1 µM, compared with negligible effect on atrial rate (β₁) or tracheal relaxation (β₂) at therapeutically relevant exposures. By contrast, the antimuscarinic tolterodine exhibits nanomolar affinity for M₂ (K_i 0.6 nM) and M₃ (K_i 0.8 nM) receptors with no β₃ activity, placing the two mechanisms in distinct efficacy–tolerability profiles.

The table illustrates that while both mirabegron and the newer agent vibegron target β₃-adrenoceptors, the latter was deliberately engineered to bypass CYP-mediated oxidation (replacing a metabolically labile amide with a pyrimidine scaffold), resulting in higher bioavailability and reduced drug–drug interaction potential. Mirabegron’s pharmacokinetics, in contrast, require dose adjustment when co-administered with moderate CYP2D6 inhibitors (e.g., terbinafine) in patients known to be CYP2D6 extensive metabolizers, and its exposure increases approximately 3.5-fold when combined with strong CYP3A4 inhibitors. Yet mirabegron remains differentiated by its extensive in vivo pharmacodynamic dataset documenting bladder compliance improvement and its availability in an osmotic controlled-release oral delivery system (OCROS) that sustains plasma concentrations above the β₃ EC₅₀ for a full 24-hour interval.

Polymorphic Form I and Its Stability Envelope

Mirabegron is known to crystallize in at least two anhydrous forms (Form I and Form II) and multiple solvates. Commercial manufacture targets Form I, the thermodynamically stable polymorph at room temperature, characterized by a monoclinic P2₁ space group with unit cell parameters a = 13.728 Å, b = 5.526 Å, c = 26.157 Å, β = 102.78°. Bulk powder identity is confirmed against a reference X-ray powder diffraction (XRPD) pattern collected with Cu Kα radiation (λ = 1.5406 Å); diagnostic peaks appear at 2θ = 6.5°, 11.9°, 14.3°, 17.8°, and 21.2°, with the 6.5° reflection serving as the primary discriminating signal against Form II. Polymorphic interconversion is a recognized process risk: Form II can nucleate during wet granulation or exposure to solvent vapors at elevated temperature. Differential scanning calorimetry reveals that Form II exhibits a melting endotherm near 128 °C, approximately 10–12 K lower than Form I, and transforms monotropically; once Form II appears, reversion to Form I without complete dissolution and recrystallization is not spontaneous. Accordingly, the active pharmaceutical ingredient specification (per Ph. Eur. monograph 2928) mandates XRPD comparison against a Form I reference diffractogram and limits Form II content to ≤5% peak area. In practice, laser Raman spectroscopy deployed in-line during crystallization from isopropanol–water mixtures provides real-time polymorph monitoring, with the Raman shift at 1698 cm⁻¹ (amide C=O stretch) exhibiting a sensitivity of approximately 0.3% w/w for Form II detection.

The synthesis of mirabegron proceeds through a convergent route: (2R)-2-hydroxy-2-phenylethanamine (chiral amino alcohol) is coupled with 2-(4-aminophenyl)ethylamine via a reductive amination, and the resulting diamine intermediate is then condensed with 2-(2-aminothiazol-4-yl)acetic acid or its activated ester. Control of the (R)-configuration is paramount—the (S)-enantiomer displays approximately 30-fold lower agonist potency at human β₃-adrenoceptors, rendering enantiomeric purity a critical quality attribute. The chiral purity specification, determined by HPLC on an amylose tris(3,5-dimethylphenylcarbamate) chiral stationary phase with a mobile phase of n-hexane–ethanol–diethylamine (80:20:0.1 v/v/v), requires ≤1.0% of the (S)-enantiomer. Batch release data from commercial manufacturing lines employing tartaric acid resolution of the racemic alcohol precursor indicate typical enantiomeric excess exceeding 99.5%, with any excursion above 0.5% (S)-content triggering a process capability investigation under ICH Q10 quality management. Residual solvents—isopropanol, methyl tert-butyl ether, and N,N-dimethylformamide—are controlled to the limits specified in USP general chapter <467>, with Class 2 solvent N,N-dimethylformamide restricted to ≤880 ppm.

When Extended-Release Formulation Meets Poor Aqueous Solubility

The approved oral formulation (Myrbetriq®) relies on an osmotic controlled-release oral delivery system (OCROS) to overcome the API’s solubility-limited absorption. A bilayer tablet consists of a drug layer containing micronized mirabegron (D90 typically <10 µm), polyethylene oxide as a swelling polymer, and a solubilizing agent such as poloxamer 188, overlaid with a polymeric push layer containing a high-viscosity polyethylene oxide (Polyox™ WSR Coagulant, approximate molecular weight 5 × 10⁶ Da). The core is coated with a semipermeable cellulose acetate membrane drilled with a 0.5 mm laser aperture. Upon ingestion, water influx through the membrane generates a hydrogel that extrudes the drug suspension at a near-zero-order rate for 16–20 hours. Dissolution testing per USP monograph employs Apparatus II (paddle) at 50 rpm in 900 mL of pH 6.8 phosphate buffer at 37 °C, with sampling at 1 h, 4 h, 8 h, and 16 h; acceptance criteria require 20–40% dissolved at 4 h and ≥75% at 16 h. In vitro–in vivo correlation (IVIVC) models developed using deconvolution of the plasma concentration–time curve indicate a Level A correlation when dissolution is conducted in the presence of 0.1% sodium lauryl sulfate to simulate intestinal surfactant levels, a nuance absent from the compendial method.

Batch-to-batch variability in particle size distribution remains the dominant source of dissolution rate fluctuation. Jet-milling operations are monitored by laser diffraction (Malvern Mastersizer 3000, dry dispersion at 2 bar) with a target D50 of 3–5 µm. Particles below 1 µm tend to agglomerate during compression, while those exceeding 15 µm reduce the effective surface area sufficiently to depress the 4-hour dissolution value toward the lower acceptance boundary. Manufacturing-scale fluid-bed granulation prior to compression mitigates these effects by embedding the API in a water-soluble matrix of mannitol and hydroxypropyl cellulose, yet any deviation in granulation endpoint (determined by power consumption trending on a Diosna P1-6 high-shear mixer) exceeding ±5% relative standard deviation in torque readout has been correlated with a 3–5% absolute decrease in the 16-hour dissolution plateau, attributed to altered porosity of the compressed tablet core. These observations anchor in-process control strategies to multivariate statistical process control (MSPC) models operating under ICH Q8 pharmaceutical development principles.

Comparisons with the newer β₃-agonist vibegron often center on the drug–drug interaction (DDI) burden: vibegron is not a substrate for CYP2D6 and carries no prominent CYP inhibition label, whereas mirabegron is a moderate CYP2D6 inhibitor (increases desipramine exposure by 3.2-fold in vivo) and a weak inhibitor of P-glycoprotein. However, mirabegron’s metabolism produces a carboxylic acid metabolite (M5) that retains approximately 10% of the parent’s β₃ potency, a feature absent in vibegron’s profile. Published data for the relative contribution of this active metabolite to detrusor relaxation at steady-state trough concentrations are limited; physiologically based pharmacokinetic models incorporating urinary bladder tissue concentrations suggest the metabolite contributes ≤5% to the overall pharmacodynamic effect, but formal experimental confirmation using isolated bladder strips from multiple human donors remains incomplete.

Specification-grade mirabegron is also offered as a reference standard for analytical method qualification, typically certified to a purity of 99.7% (area percent by HPLC at 254 nm) with a stated expanded uncertainty of ±0.5% (coverage factor k = 2). When employed as an impurity marker in stress degradation studies, forced decomposition under ICH Q1A(R2) conditions—acidic hydrolysis (1 M HCl, 80 °C/48 h), oxidative stress (3% H₂O₂, ambient/6 h), and photolysis (ICH Q1B option 2, 1.2 × 10⁶ lux·h visible, 200 W·h/m² UV)—generates a primary degradation product, des-(2-aminothiazole) mirabegron, which must be resolved with a chromatographic separation factor of at least 1.5 from the parent peak. The related substances method, operating on a C18 column (150 × 4.6 mm, 3 µm) with a gradient of acetonitrile–phosphate buffer (pH 3.0), quantifies this degradant at a reporting threshold of 0.05%, consistent with ICH Q3B requirements for a maximum daily dose of 50 mg.